Medtronic is modestly undervalued based on DCF analysis, but slow revenue growth limits upside potential. Read why I ...

NeurAxis (NASDAQ:NRXS – Get Free Report) and Medtronic (NYSE:MDT – Get Free Report) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength ...

Medtronic's 780g insulin pump automates much of the insulin delivery and can be integrated its own CGM or Libre. Though these competitive features could have peeled some Dexcom users away on the ...

Abbott's Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose ...

In the third quarter, in Diabetes Care, sales of CGM exceeded $1.6 billion and grew 21%. In August, the company announced that it has entered into a unique global partnership with Medtronic to ...

Among the highlights is its partnership with Medtronic, integrating Abbott's continuous glucose monitoring (CGM) systems with Medtronic's insulin delivery devicesfurther strengthening Abbott's ...

Beta Bionics announced today that it launched the integration of the iLet bionic pancreas with the Abbott (NYSE:ABT) ...

Global Remote Patient Monitoring Market is estimated to be valued at $40B in 2023, expected to grow at CAGR of ~12% during the forecast period (2024 – 2030) ...

The global injection pen market is poised for significant growth, with projections indicating a robust compound annual growth rate (CAGR) of 7.0% from 2022 to 2033. The market is expected to escalate ...

England's NHS is testing an artificial pancreas for children with Type 1 diabetes, a device already available in India.

has made significant headway in a project to develop its own CGM. In addition to DexCom (DXCM) and Abbott (ABT), Medtronic ...